ARTICLE | Company News
Orion, Bayer deal
June 9, 2014 7:00 AM UTC
The companies partnered to co-develop and commercialize Orion's ODM-201, which has completed a Phase I/II trial in metastatic castration-resistant prostate cancer (CRPC). Orion will receive €50 milli...